Mittie Doyle Sells 1,450 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Mittie Doyle sold 1,450 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the completion of the transaction, the insider owned 51,776 shares of the company’s stock, valued at approximately $931,968. This represents a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Monday, April 6th, Mittie Doyle sold 3,970 shares of Avalo Therapeutics stock. The stock was sold at an average price of $18.01, for a total value of $71,499.70.
• On Wednesday, April 1st, Mittie Doyle sold 679 shares of Avalo Therapeutics stock. The stock was sold at an average price of $16.00, for a total value of $10,864.00.

Avalo Therapeutics Stock Down 0.9%

Shares of NASDAQ AVTX traded down $0.16 during trading hours on Thursday, hitting $18.00. The company had a trading volume of 1,689,258 shares, compared to its average volume of 1,168,646. Avalo Therapeutics, Inc. has a 1-year low of $4.53 and a 1-year high of $24.27. The firm’s 50 day moving average is $15.75 and its 200-day moving average is $16.09. The stock has a market capitalization of $946.26 million, a P/E ratio of -3.30 and a beta of 0.83.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.02. On average, sell-side analysts predict that Avalo Therapeutics, Inc. will post -2.58 earnings per share for the current year.

Institutional Investors Weigh In On Avalo Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. PFS Partners LLC grew its stake in shares of Avalo Therapeutics by 100.0% in the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after acquiring an additional 1,000 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in Avalo Therapeutics in the 3rd quarter worth about $143,000. Boothbay Fund Management LLC acquired a new stake in Avalo Therapeutics in the 2nd quarter worth about $56,000. AlphaCentric Advisors LLC bought a new stake in Avalo Therapeutics in the 1st quarter valued at about $174,000. Finally, Jump Financial LLC acquired a new position in shares of Avalo Therapeutics during the 4th quarter worth approximately $238,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on AVTX shares. Mizuho raised their target price on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. Wall Street Zen raised Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, March 29th. BTIG Research reaffirmed a “buy” rating and set a $58.00 price target on shares of Avalo Therapeutics in a report on Tuesday, June 16th. Bank of America initiated coverage on shares of Avalo Therapeutics in a research report on Friday, June 12th. They set a “buy” rating and a $35.00 price objective for the company. Finally, Wedbush dropped their price objective on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a research report on Thursday, May 14th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Avalo Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $46.67.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.